Literature DB >> 23121366

T-cell responses to hepatitis B splice-generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP-FIBRO.

F Bayard1, O Godon, B Nalpas, C Costentin, R Zhu, P Soussan, A Vallet-Pichard, H Fontaine, V Mallet, S Pol, M-L Michel.   

Abstract

A new hepatitis B virus (HBV) protein, hepatitis B splice-generated protein (HBSP), has been detected in liver biopsy specimens from patients with chronic active hepatitis. The aim of this study was to characterize the phenotype and functions of peripheral HBSP-specific T cells and to determine whether these T-cell responses may be implicated in liver damage or viral control. Two groups of patients were studied: HBV-infected patients with chronic active hepatitis and HBV-infected patients who were inactive carriers of hepatitis B surface antigen. HBSP-specific T-cell responses were analysed ex vivo and after in vitro stimulation of peripheral blood mononuclear cells. Soluble cytokines and chemokines were analysed in sera and in cell culture supernatants. Few HBSP- or capsid-specific T-cell responses were detected in patients with chronic active hepatitis whereas frequency of HBV-specific T cells was significantly higher in inactive carrier patients. HBSP activated CD8+ and CD4+ T cells that recognized multiple epitopes and secreted inflammatory cytokines. The IL-12 level was significantly lower in sera from asymptomatic carrier patients compared to patients with chronic active hepatitis. IL-12 and IP-10 levels in the sera were significantly and independently correlated with both alanine amino transferase and HBV DNA levels. Our results show that the HBSP protein activates cellular immune responses in HBV-infected patients but has probably no prominent role in liver damage. The pattern of cytokines and chemokines in sera was linked to HBV viral load and was consistent with the level of inflammation during chronic hepatitis.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23121366     DOI: 10.1111/j.1365-2893.2012.01611.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  7 in total

1.  Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues.

Authors:  O Godon; H Fontaine; S Kahi; J F Meritet; D Scott-Algara; S Pol; M L Michel; M Bourgine
Journal:  Mol Ther       Date:  2013-12-05       Impact factor: 11.454

Review 2.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

3.  Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity.

Authors:  Marion Duriez; Yassmina Mandouri; Bouchra Lekbaby; Hualin Wang; Aurélie Schnuriger; Francois Redelsperger; Chiara Ida Guerrera; Marine Lefevre; Veronique Fauveau; James Ahodantin; Ivan Quetier; Cerina Chhuon; Samir Gourari; Alexandre Boissonnas; Upkar Gill; Patrick Kennedy; Nabil Debzi; Delphine Sitterlin; Mala K Maini; Dina Kremsdorf; Patrick Soussan
Journal:  J Hepatol       Date:  2017-06-07       Impact factor: 25.083

4.  Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population.

Authors:  Zhihui Xu; Yan Liu; Liming Liu; Xiaodong Li; Siyu Bai; Yihui Rong; Haibin Wang; Yuanli Mao; Shaojie Xin; Dongping Xu
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

5.  Secreted hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection.

Authors:  Olivia Maslac; Josef Wagner; Vitina Sozzi; Hugh Mason; Jenny Svarovskaia; Susanna Tan; Anuj Gaggar; Stephen Locarnini; Lilly Yuen; Margaret Littlejohn; Peter A Revill
Journal:  J Viral Hepat       Date:  2022-05-28       Impact factor: 3.517

6.  Suppression of gelatinase activity in human peripheral blood mononuclear cells by verapamil.

Authors:  Fatemeh Hajighasemi; Neda Kakadezfuli
Journal:  Cell J       Date:  2014-02-03       Impact factor: 2.479

Review 7.  Nature of Host Immunity during Hepatitis B Virus Infection and designing Immune Therapy.

Authors:  Sheikh Mf Akbar; Mamun Al-Mahtab; Sakirul I Khan
Journal:  Euroasian J Hepatogastroenterol       Date:  2018-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.